Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists.

National Heart, Lung, and Blood Institute's The Framingham Heart Study, Framingham, Massachusetts, USA.
Nature Genetics (Impact Factor: 29.65). 07/2010; 42(7):608-13. DOI: 10.1038/ng.604
Source: PubMed

ABSTRACT Platelet function mediates both beneficial and harmful effects on human health, but few genes are known to contribute to variability in this process. We tested association of 2.5 million SNPs with platelet aggregation responses to three agonists (ADP, epinephrine and collagen) in two cohorts of European ancestry (N<or=2,753 in the Framingham Heart Study, N<or=1,238 in the Genetic Study of Atherosclerosis Risk). We identified associations of seven loci with platelet aggregation near or within GP6 (P=4.6x10(-13)), PEAR1 (P=3.4x10(-12)), ADRA2A (P=3.3x10(-11)), PIK3CG (P=3.1x10(-9)), JMJD1C (P=1.6x10(-8)), MRVI1 (P=2.0x10(-8)) and SHH (P=4.5x10(-8)). Six of these loci replicated at P<0.05 in an additional African-American cohort (N<or=840 in the Genetic Study of Atherosclerosis Risk). These results provide insights into platelet aggregation pathways and may suggest new antiplatelet therapeutic targets.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Platelets are crucial subcellular elements of haemostasis at sites of vascular injury and are also known to be immune mediators in pathological thrombosis. Despite the integral role of platelets in many disease processes, there is very little information available on platelet function and response to agonists in healthy children. We recently reported important differences in the interaction of platelets with monocytes in the circulation, including increased formation of monocyte-platelet aggregates (MPAs) without concomitant increase in P-selectin expression. Our current study investigates parameters of platelet activation (PAC-1 binding and P-selectin expression) and MPA formation in response to a range of physiologically relevant platelet agonists in healthy children compared to healthy adults. All parameters were significantly higher in children in response to sub-maximal concentrations of thrombin receptor activator peptide and adenosine diphosphate, reflecting an age-specific difference in agonist-stimulated platelet reactivity in children. The results of our study challenge the general assumption that platelet reactivity in children is similar to adults. This finding is fundamental to investigating the role of platelets in diseases of childhood and pathogenesis of adult-based diseases that have their origins in childhood. Our findings underscore the need for age-specific reference ranges for platelet function in children rather than extrapolation from adult data.
    British Journal of Haematology 09/2014; DOI:10.1111/bjh.13153 · 4.94 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Platelet aggregation during aspirin treatment displays considerable inter-individual variability. A genetic etiology likely exists, but it remains unclear to what extent genetic polymorphisms determine platelet aggregation in aspirin-treated individuals. Aim: To identify platelet-related single nucleotide polymorphisms (SNPs) influencing platelet aggregation during aspirin treatment. Furthermore, we explored to what extent changes in cyclooxygenase-1 activity and platelet activation may explain such influence. Methods: We included 985 Danish patients with stable coronary artery disease treated with aspirin 75 mg/day mono antiplatelet therapy. Patients were genotyped for 16 common SNPs in platelet-related genes using standard PCR-based methods (TaqMan). Platelet aggregation was evaluated by whole blood platelet aggregometry employing Multiplate Analyzer (agonists: arachidonic acid and collagen) and VerifyNow Aspirin. Serum thromboxane B-2 was measured to confirm aspirin adherence and was used as a marker of cyclooxygenase-1 activity. Soluble P-selectin was used as marker of platelet activation. Platelet aggregation, cyclooxygenase-1 activity, and platelet activation were compared across genotypes in adjusted analyses. Results: The A-allele of the rs12041331 SNP in the platelet endothelial aggregation receptor-1 (PEAR1) gene was associated with reduced platelet aggregation and increased platelet activation, but not with cyclooxygenase-1 activity. Platelet aggregation was unaffected by the other SNPs analyzed. Conclusion: A common genetic variant in PEAR1 (rs12041331) reproducibly influenced platelet aggregation in aspirin-treated patients with coronary artery disease. The exact biological mechanism remains elusive, but the effect of this polymorphism may be related to changes in platelet activation. Furthermore, 14 SNPs previously suggested to influence aspirin efficacy were not associated with on-aspirin platelet aggregation.
    PLoS ONE 10/2014; 9(10):e111816. DOI:10.1371/journal.pone.0111816 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human platelets express two thrombin receptors, protease activated receptor (PAR) 1 and PAR4. Recently we reported 3.7-fold increased PAR4-mediated aggregation kinetics in platelets from black subjects compared to white subjects. We now show that platelets from blacks (n=70) express 14% more PAR4 protein than whites (n=84), but this difference is not associated with platelet PAR4 function. Quantitative trait locus analysis identified three common SNPs in the PAR4 gene (F2RL3) associated with PAR4-induced platelet aggregation. Among these SNPs, rs773902 determines whether residue 120 in transmembrane domain 2 is an alanine (Ala) or threonine (Thr). Compared to the Ala120 variant, Thr120 was more common in black than white subjects (63% vs. 19%), associated with higher PAR4-induced human platelet aggregation and Ca(2+) flux, and generated greater inositol 1,4,5-triphosphate (IP3) in transfected cells. A second, less frequent F2RL3 variant, Phe296Val, was only observed in blacks and abolished the enhanced PAR4-induced platelet aggregation and IP3 generation associated with PAR4-Thr120. PAR4 genotype did not affect vorapaxar inhibition of platelet PAR1 function, but a strong pharmacogenetic effect was observed with the PAR4-specific inhibitor YD-3. These findings may have an important pharmacogenetic impact on development of new PAR inhibitors.
    Blood 10/2014; 124(23). DOI:10.1182/blood-2014-04-572479 · 9.78 Impact Factor

Full-text (2 Sources)

Available from
Jun 10, 2014